$TDAY

Barclays upgrades USA Today stock rating on Google antitrust ruling

Citizens upgraded USA Today (TDAY) to Market Outperform with a $10.00 price target after a court ruling in its antitrust case against Google. The stock is up 10% this week and 70% over the past year. The ruling allows most of USA Today's claims to proceed, and the firm expects a settlement. Q1 2026 digital revenue beat estimates by 1%, with EBITDA exceeding expectations by $16 million.

Original reporting
Published Oct 2, 2026, 9:08 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 2, 2026, 9:17 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$TDAY
Bullish
high confidence
Mentioned
$TDAY
Relevance
6/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$TDAYBullishMed
01

Why it matters

The legal outcome keeps USA Today's claims alive, supporting a higher valuation.

02

Market read

Rating upgrade and price target raise provide a fresh catalyst for TDAY.

03

What to watch

Potential costs of prolonged litigation and broader ad‑tech market dynamics.

Relevance 6/10Novelty 7/10Timing: pre‑market today

Background

USA Today faced an antitrust lawsuit from Google; the court denied most of Google's summary‑judgment motions.

Company-level read

Ticker impact

$TDAYBullishHigh confidence
Context

Citizens reiterates a Market Outperform rating and raises the price target to $10 after a court ruling in USA Today's antitrust case against Google.

Expected impact

likely upward pressure as investors price in the rating upgrade and potential settlement.

Evidence & confidence

The rating change is a fresh, material catalyst for a sub‑$2B cap stock.

Market effects

Media and publishing sector may see modest uplift from the legal win.

U.S. market sentiment for small‑cap media stocks could improve.

Limited to U.S. listed media companies.

Counterpoint

The ruling may not lead to a settlement soon, limiting upside.

Key entities

  • USA Today

    Media publisher listed on NYSE as TDAY.

  • Google

    Defendant in the antitrust case.

Related articles

$TDAYMed

USA Today Q2 Earnings Call Highlights

USA TODAY Media, part of Gannett (NYSE: GCI), reported Q2 digital-only subscription revenue up 6.8% to $45.6M and digital-only ARPU up 34.4% to a record $10.47. Digital other revenue rose 20.2% to $20.4M. Management discussed AI licensing, DeeperDive usage, and a Palantir project for first-party data, with no benefit included in the current full-year forecast.

$TDAYMed

USA TODAY Co. Announces Second Quarter Results & Reiterates Business Outlook

USA TODAY Co., Inc. (TDAY) filed an SEC Form 8-K — Results of Operations and Financial Condition. USA TODAY Co. Announces Second Quarter Results & Reiterates Business Outlook NEW YORK, NY — August 6, 2026 — USA TODAY Co., Inc. ("USA TODAY Co.", "we", "us", "our", or the "Company") (NYSE: TDAY) today reported its financial results for the second quarter ended June 30, 2026. "T

$TDAYMedAI 8/10

USA Today (NYSE:TDAY) Hits New 52

USA Today Co. (NYSE:TDAY) shares hit a new 52-week high on Wednesday, trading up to $7.82 and last at $7.75 versus a prior close of $7.73, with 37,301 shares traded. Analysts cited include a Citigroup neutral and a Rosenblatt sell; MarketBeat reports an average “Hold” and $7.70 consensus target. The company reported Feb. 26 quarterly EPS of ($0.21) on $585M revenue.

$MRNAHigh

MRNA Stock’s Vaccine Rally Cracks As Worst Week In 3 Months Looms — Analyst Calls It A ‘Do-Not-Trade’ Over Wild Swings

Moderna (MRNA) shares fell sharply, marking their worst week in three months. Analysts from Bernstein, TD Cowen, and BMO Capital Markets expressed mixed views on the company's cancer vaccine data, with price targets implying significant downside. Moderna reported a revenue decline in 2025 and aims for cash breakeven by 2028. Earnings are due on Nov. 6. Retail sentiment on Stocktwits remains bullish for both Moderna and Merck (MRK).